Tuberculous Meningitis in Indonesia: Characteristics, Treatments, Diagnostics, and Outcomes (2022–2025)
Official title: Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis: A Retrospective Cohort Study in Indonesia, 2022-2025
Run by Ina-Respond · NCT07929519 · Data updated 2026-11-12
This study looks back at TB meningitis patients treated in several Indonesian hospitals from 2022 to 2025 to describe their symptoms, tests, treatments, and outcomes using existing medical records.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Ina-Respond Academic / other |
| Locations | 6 sites (Denpasar, Bali and 5 other locations) |
| Status | Recruiting |
| Started | September 24, 2026 |
| Main results expected | August 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07929519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients admitted to the participating hospitals from January 1, 2022, to December 31, 2025 with a TBM diagnosis or documented TBM in the EMR and with accessible EMR data.
✕Probably not a fit
Patients without complete EMR data or not meeting the timing window may not contribute to all study analyses.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, observational, retrospective cohort study of TB meningitis patients admitted between 2022 and 2025. Data are drawn from electronic medical records at six participating hospitals and collected at five predefined timepoints: admission, treatment start, discharge, end of intensive phase, and end of treatment. No new interventions are performed; the study analyzes existing clinical information to characterize characteristics, diagnostics, treatment regimens, complications, and outcomes. The study aims to illuminate real-world patterns of care and outcomes for TB meningitis in Indonesia. Inclusion requires a TBM diagnosis or ICD-10 code A17.0 and available EMR data; there are no listed exclusion criteria.
Why it matters
Potential benefit: If successful, the study could improve understanding of TB meningitis care in Indonesia and inform future clinical guidelines and health policy.
How similar studies have gone: Prior observational studies of TBM have provided valuable descriptive data; this multicenter Indonesian study adds regional context but remains observational in nature.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admited to the participating hospital sites between January 1, 2022, and December 31, 2025 * Have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system. * Have accessible data available in the EMR. Exclusion Criteria: None
Where it's running
-
Site 701: RS Pusat Otak Nasional Prof. Dr. dr. Mahar Mardjono (RSPON)
Jakarta, DKI Jakarta, Indonesia Recruiting -
Site 540: RS Penyakit Infeksi Prof. Dr. Sulianti Saroso (RSPI SS)
Jakarta, DKI Jakarta, Indonesia Recruiting -
Site 704: RSUP dr Johannes Leimena
Ambon City, Maluku, Indonesia Recruiting -
Site 702: RSUP dr Mohammad Hoesin
Palembang, South Sumatra, Indonesia Recruiting -
Site 703: RSUP dr M Djamil
Padang, West Sumatra, Indonesia Recruiting -
Site 520: RSUP Prof Dr I.G.N.G. Ngoerah
Denpasar, Bali, Indonesia Not yet recruiting
Study contacts
- Principal investigator: dr. Robert Sinto, SpPD,, K-PTI, DPhil, FINASIM, FHEA — Indonesia Research Partnership on Infectious Disease (INA-RESPOND)
- Study coordinator: dr. M. Helmi Aziz, M.Sc., Sp.MK
- Email: mhazis@ina-respond.net
- Phone: +62 858-5458-0905
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BPaLMZ for TB Meningitis: a two-stage trial comparing an experimental regimen to standard therapy
This phase 2 trial tests whether the BPaLMZ combination can be better than standard TB meningitis treatment in adults living with HIV who have TB meningitis.
-
Using adalimumab to improve survival in HIV patients with tuberculosis meningitis
This study is testing if adding a medication called adalimumab to the usual treatment can help HIV patients with tuberculosis meningitis live longer and stay safe.
-
Six-month high-dose rifampicin and isoniazid with linezolid and pyrazinamide versus standard nine-month therapy for adult and adolescent tuberculous meningitis
This study tests whether a six-month, high-dose antibiotic regimen (rifampicin, isoniazid, linezolid, and pyrazinamide) works better than the WHO nine-month treatment for adults and adolescents with tuberculous meningitis.
-
Intensified treatment for tuberculous meningitis to reduce mortality
This study is testing if a stronger treatment for tuberculous meningitis can help people survive better than the standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.